NHS pelvic mesh scandal
The NHS pelvic mesh scandal concerns the widespread use of synthetic surgical mesh—particularly transvaginal mesh and mesh tapes/slings—to treat women with stress urinary incontinence (SUI) and pelvic organ prolapse (POP). For some women, the implants caused severe and sometimes irreversible complications. The scandal became as much about failure to listen to patients, inadequate consent, poor device surveillance and fragmented regulation as about the mesh itself.
1. What was the mesh used for?
From the late 1990s onwards, synthetic polypropylene mesh was increasingly used in procedures including:
Mid-urethral mesh slings/tapes for stress urinary incontinence.
Transvaginal mesh to reinforce weakened tissues in pelvic organ prolapse.
Other mesh procedures, including abdominal and rectal prolapse surgery, although the main controversy centred on vaginally inserted mesh.
The attraction was understandable: these were relatively quick procedures that could avoid more extensive conventional surgery.
The problem was that mesh is designed to become incorporated into surrounding tissue. If complications occur, removing it can therefore be extremely difficult.
2. What went wrong?
Women began reporting serious complications including:
chronic pelvic and vaginal pain;
mesh erosion or exposure through vaginal tissue;
mesh erosion into the bladder, urethra or bowel;
recurrent infections and bleeding;
urinary and bowel dysfunction;
painful sexual intercourse;
nerve damage and leg/buttock pain;
difficulty walking and exercising;
psychological consequences associated with persistent pain and disability.
NHS guidance itself recognises symptoms including pelvic pain, bleeding/discharge, recurrent bladder or bowel problems, pain during intercourse and severe buttock or leg pain.
One particularly difficult feature was that mesh removal was not necessarily a straightforward cure. Because tissue grows around the implant, complete removal can require complex surgery and may itself cause injury.
3. Why did this become an NHS scandal rather than simply a complication of surgery?
This is the crucial issue.
Thousands of women argued that they had not been adequately warned of the potential severity or permanence of complications. Some subsequently reported that when they developed symptoms, clinicians did not recognise or accept that the mesh could be responsible.
The wider problem was systemic. There was no sufficiently robust mechanism for identifying implanted devices, tracking long-term outcomes and combining adverse-event information across the NHS.
The eventual independent review was established specifically to examine how the healthcare system responded when patients and families raised concerns about treatment safety.
This makes mesh an important example of a broader patient-safety problem:
individual patient reports existed, but the system was poor at aggregating those reports into an early national safety signal.
4. The Cumberlege Review
In 2018, Jeremy Hunt commissioned an independent review chaired by Baroness Julia Cumberlege. It examined three major patient-safety controversies:
pelvic mesh;
sodium valproate taken during pregnancy; and
the hormone pregnancy test Primodos.
Its landmark report, First Do No Harm, was published on 8 July 2020.
The report was highly critical of the healthcare system’s response to patients. It identified a culture in which patients—overwhelmingly women in these cases—had too often not been listened to, while the health system was slow to recognise patterns of harm.
It made nine strategic recommendations and 50 actions for improvement.
Among the most important were an apology, creation of a Patient Safety Commissioner, specialist mesh centres, better recording and tracking of implanted medical devices, and arrangements for redress.
5. The 2018 suspension of mesh
Even before the final Cumberlege report, the Review recommended an immediate pause.
In July 2018, the government accepted this and introduced what became known as the High Vigilance Restriction on vaginally inserted mesh for prolapse and mesh tape/slings for stress urinary incontinence.
Importantly, this was technically not an absolute statutory ban. It was a national restriction intended to remain until stringent safety conditions were satisfied.
And this remains important today: as of 2026, the national pause remains in place.
6. What has the NHS subsequently done?
A major response has been creation of nine specialist NHS mesh centres in England:
Cambridge, Manchester, Newcastle, Nottingham, Sheffield, UCLH in London, Leicester, Southampton and North Bristol.
These are intended to provide genuinely multidisciplinary assessment involving surgeons, physicians, specialist nurses, imaging, pain specialists, physiotherapy and psychological support.
There has also been a major change in device surveillance. NHS England now operates the Medical Devices Outcomes Registry (MDOR), established in 2024, designed to collect patient-identifiable information about implanted devices and outcomes—a direct consequence of the Cumberlege recommendations.
There is additionally a specific Pelvic Organ Prolapse and Stress Urinary Incontinence (POPSUI) Registry, designed to provide much better outcome information on these procedures.
7. How many women have been affected?
This is surprisingly difficult to answer precisely—and that is itself part of the scandal.
Historically, inadequate implant registries and inconsistent coding meant the NHS could not reliably identify every woman who had received a particular mesh product or determine systematically what happened to them.
What we can say more confidently is that the specialist services continue to see substantial numbers. In June 2026 the Government reported that nearly 3,000 patients had been seen by England’s specialist mesh centres since their introduction, approximately 700 a year.
That figure should not be interpreted as the total number harmed. It represents patients seen within the specialist-centre system.
8. The unresolved issue: compensation and redress
This remains one of the most contentious parts of the story.
Cumberlege recommended an independent redress agency and specific redress arrangements. The Government did not accept those recommendations in their original form.
The issue was subsequently reconsidered by England’s Patient Safety Commissioner. The resulting Hughes Report, published in February 2024, recommended a two-stage redress scheme providing financial and non-financial support for people harmed by pelvic mesh and sodium valproate.
As of 2026, the Government is still working on its response. Officials are assessing the number of people affected and the financial impact alongside the Treasury, Cabinet Office and devolved administrations.
9. Why the mesh scandal matters for NHS patient safety
For me, the most important lesson is not simply “mesh was unsafe.” The picture is more nuanced than that: mesh can have clinical benefits in selected circumstances, and complications do not occur in every patient.
The deeper failure was the pathway by which harm was detected:
Patient develops unexpected symptoms → patient reports them → individual clinician treats them as an isolated case → reporting/data systems fail to connect cases → national safety signal develops slowly → thousands more procedures can occur before policy changes.
That is precisely why First Do No Harm is so significant. The scandal exposed weaknesses in informed consent, longitudinal outcome measurement, medical-device traceability, adverse-event reporting, clinical response to patient testimony and institutional accountability.
The establishment of the Patient Safety Commissioner for England was a direct consequence of those findings.